COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is thrilled to welcome Dr. Ivan Goldsmith of Trimcare in Las Vegas, Nevada, into the fold. Cannabis Science and Dr. Goldsmith are teaming up to implement novel treatments for obesity, metabolic syndrome, and hormone deficiency syndromes, backed by the research and science by Cannabis Science and Dr. Goldsmith. He sits as the Nevada state representative on the scientific advisory board for Cannabis Science.
Dr. Goldsmith is a leading medical authority on weight management and patient self-esteem issues. He brings with him 20 years of experience, as well as being triple board certified in Internal Medicine, Anti-aging, and Bariatrics. His company, Trimcare, has treated in excess of 25,000 Las Vegans. The weight loss program includes medication targeting appetite suppression and increasing the body’s natural energy for effective metabolism, as well as meal programs. Trimcare’s philosophy has been to utilize alternative complementary medicine. With Cannabis Science, Trimcare will be actively involved in implementing breakthroughs from cutting edge research on the endocannabinoid system. Not only will weight loss be targeted, but other ailments such as chronic pain, anti-aging, and infectious and metabolic disorders.
Trimcare also focuses on cosmetic procedures, a unique diet based on the patient’s DNA and customized to the patient’s genotype, and hormonal replacement therapy, and smoking cessation. You can learn more about Trimcare at their website, www.trimcare.com.
Dr. Goldsmith says about this new relationship, “We have been pioneers in the implementation of novel treatments for obesity, metabolic syndrome and hormone deficiency syndromes. Our mission has been to enhance wellness and life expectancy through product offerings that encourage patients to participate with us in this journey.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.